AstraZeneca Plc (AZN)

36.98
0.10 0.27
NYSE : Health Technology
Prev Close 36.88
Open 36.82
Day Low/High 36.74 / 37.04
52 Wk Low/High 28.43 / 37.30
Volume 3.26M
Avg Volume 3.97M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 91.99B
EPS 1.20
P/E Ratio 16.52
Div & Yield 1.37 (3.70%)

Latest News

4 Great Dividend Stocks That Always Remember to Say 'Thank You': Market Recon

4 Great Dividend Stocks That Always Remember to Say 'Thank You': Market Recon

These dividend payers compete in businesses that I'm interested in and believe in -- and they pay me to own the shares.

Watch Oncology Stocks Ahead of 2 Big Events

Watch Oncology Stocks Ahead of 2 Big Events

Data and industry conferences will likely be catalysts for shares in the space.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

US FDA Approves BYDUREON For Use With Basal Insulin In Patients With Type 2 Diabetes With Inadequate Glycemic Control

US FDA Approves BYDUREON For Use With Basal Insulin In Patients With Type 2 Diabetes With Inadequate Glycemic Control

AstraZeneca today announced the US Food and Drug Administration (FDA) has approved BYDUREON ® (exenatide extended-release) for injectable suspension as an add-on therapy to basal insulin in adults with type 2 diabetes...

US FDA Accepts Biologics License Application For Moxetumomab Pasudotox In Hairy Cell Leukemia

US FDA Accepts Biologics License Application For Moxetumomab Pasudotox In Hairy Cell Leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for moxetumomab pasudotox, an...

AstraZeneca Presents New Data Evaluating Safety And Efficacy Of FARXIGA In Patients With Type 2 Diabetes And Moderate Renal Impairment

AstraZeneca Presents New Data Evaluating Safety And Efficacy Of FARXIGA In Patients With Type 2 Diabetes And Moderate Renal Impairment

AstraZeneca today announced the results of DERIVE, a Phase 3 study that evaluated the efficacy and safety of FARXIGA ® (dapagliflozin 10 mg), in patients with type 2 diabetes (T2D) with moderate renal impairment...

AstraZeneca Announces Renewed Recommendation And Availability Of FLUMIST QUADRIVALENT Vaccine In The US

AstraZeneca Announces Renewed Recommendation And Availability Of FLUMIST QUADRIVALENT Vaccine In The US

AstraZeneca today announced that the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) has voted in favor of a renewed recommendation for the use of FLUMIST ®...

Ionis Licences New Antisense Drug For Kidney Disease To AstraZeneca

Ionis Licences New Antisense Drug For Kidney Disease To AstraZeneca

Ionis earns $30 million license fee

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

Quanterix Uses JPMorgan Healthcare Conference to Scout Sales Candidates

With a boost from the NFL and its own IPO, Quanterix hopes to engage biopharma companies to use its platform to speed safety and efficacy results for neurology, oncology and inflammation pipelines.

LYNPARZA® (olaparib) Approved By US FDA In Germline BRCA-Mutated Metastatic Breast Cancer

LYNPARZA® (olaparib) Approved By US FDA In Germline BRCA-Mutated Metastatic Breast Cancer

AstraZeneca and Merck (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA ® (olaparib), for use in patients with deleterious or...

US FDA Accepts Regulatory Submission For TAGRISSO (Osimertinib) In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

US FDA Accepts Regulatory Submission For TAGRISSO (Osimertinib) In 1st-Line EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for the use of TAGRISSO ® (osimertinib), a third-generation, irreversible epidermal...

AstraZeneca's CALQUENCE® (acalabrutinib) Shows Potential In Chronic Lymphocytic Leukemia Trials

AstraZeneca's CALQUENCE® (acalabrutinib) Shows Potential In Chronic Lymphocytic Leukemia Trials

AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II...

AstraZeneca's CALQUENCE® (acalabrutinib) Demonstrates Activity In Relapsed Or Refractory Mantle Cell Lymphoma Trial

AstraZeneca's CALQUENCE® (acalabrutinib) Demonstrates Activity In Relapsed Or Refractory Mantle Cell Lymphoma Trial

AstraZeneca and Acerta Pharma, its hematology research and development center of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the...

AstraZeneca To Highlight Its Commitment To Blood Cancers At The 2017 American Society Of Hematology Annual Meeting

AstraZeneca To Highlight Its Commitment To Blood Cancers At The 2017 American Society Of Hematology Annual Meeting

AstraZeneca, along with Acerta Pharma, its hematology research and development center of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in blood cancer...

Celebrity Trainer And Author Bob Harper Teams Up With AstraZeneca To Connect With Fellow Heart Attack Survivors

Celebrity Trainer And Author Bob Harper Teams Up With AstraZeneca To Connect With Fellow Heart Attack Survivors

Bob Harper, celebrity personal trainer, author and heart attack survivor, is teaming up with AstraZeneca to help people like him who have experienced a heart attack share their stories to educate and inspire others.

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche Stock Surges on Trial Successes in Cancer, Haemophilia

Roche sees success in trials for its cancer and hemophilia drugs

FASLODEX® (fulvestrant) Receives US FDA Approval For The Treatment Of Advanced Breast Cancer In Combination With Abemaciclib

FASLODEX® (fulvestrant) Receives US FDA Approval For The Treatment Of Advanced Breast Cancer In Combination With Abemaciclib

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a new indication for FASLODEX ® (fulvestrant), expanding the indication to include use with abemaciclib, a CDK4/6 inhibitor, for...

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

It's Been a Fine Earnings Season, but Here Come the Retailers: Market Recon

Surviving the age of Amazon is all there is to retailers' earnings.

AstraZeneca Stock Gains as Crestor Sales Decline Slows

AstraZeneca Stock Gains as Crestor Sales Decline Slows

Sales in China picked up as decline in Crestor revenue slowed.

AstraZeneca Shares Scientific Updates From Its Extensive Cardiovascular, Renal And Metabolic Diseases (CVMD) Portfolio At AHA 2017

AstraZeneca Shares Scientific Updates From Its Extensive Cardiovascular, Renal And Metabolic Diseases (CVMD) Portfolio At AHA 2017

AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two...

FDA Approves AstraZeneca's Blood Cancer Drug

FDA Approves AstraZeneca's Blood Cancer Drug

With newly approved Calquence in hand, AstraZenca is set to compete against J&J-AbbVie's Inbruvica first on mantle cell lymphoma but down the road the challenge could be on more common blood cancers.

Geron Shares Rise on Fast Track Designation -- Biotech Movers

Geron Shares Rise on Fast Track Designation -- Biotech Movers

The FDA granted fast track designation to imetelstat as a potential treatment for adults with with transfusion-dependent anemia.

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Positive Earnings Drive Dow to New Record in Best Performance in a Month

Powerhouse performances from Caterpillar and 3M inspire a Dow rally, leading the index to new all-time highs in its 54th record close of the year.

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Dow Rises 200 Points With Records in Grasp After Caterpillar, 3M Earnings

Better-than-expected earnings from a number of key Dow components sweep markets higher.

TheStreet Quant Rating: B (Buy)